Illumina strikes $325M deal to end years-long patent battles
After spending the last 10-plus years in court, Illumina and BGI Group have reached a $325 million settlement to resolve a number of patent and antitrust claims across the US centered around the companies’ DNA sequencing technology.
Illumina is forking over the $325 million to settle claims following two recent jury decisions in Delaware and California, as well as an antitrust case in California, according to a statement on Thursday from MGI Tech, a BGI affiliate.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.